The outcome of patients with AML with BCR::ABL1 receiving standard chemotherapy without allogeneic hematopoietic cell transplantation (allo‐HCT) was poor in the non‐tyrosine kinase inhibitor (TKI) era [4, 5]. The gene discussed is BCR; the disease is acute myeloid leukemia.